******Falcon Flex hype vs limited public monetization metrics** [developing]** [developing]** [developing]
Key Questions
What were the key Q4 FY26 financial results for CrowdStrike's Falcon Flex?
Falcon Flex revenue reached $1.69B, up 120%, with $1B in net new ARR increasing 25% and FCF at $376M. These figures highlight strong performance despite growth slowdown concerns.
Why did CrowdStrike's stock slide after Q4 earnings?
The stock dropped 7.5% post-earnings to around $399, amid a growth slowdown from 35% to 22-23% and FY27 guidance of 20-25%. Technical analysis remains bearish, targeting $368.
What is the latest on CrowdStrike's share buyback program?
CrowdStrike announced a $500M expansion via 8-K, bringing total authorization to $1.5B. The CFO cited a 'valuation disconnect' as rationale.
How did CrowdStrike's stock react after the earnings dip?
After dipping to $398, the stock bounced between $398-417 and rose 5.88% on April 7. Year-to-date performance is down 12.1%.
What recognition did CrowdStrike receive from Gartner?
CrowdStrike achieved 98% in Gartner's MDR report, named a Customers’ Choice in the 2026 Peer Insights ‘Voice of the Customer’ for Managed Detection and Response.
What is Jim Cramer's opinion on CrowdStrike stock?
Jim Cramer views CrowdStrike as a buying opportunity, especially with the company repurchasing its 'beat-up' stock.
What are the current analyst price targets for CrowdStrike?
Price targets range from $400s to $520, with a median of $505 implying 20% upside; Zacks rates it at 105x. Minor institutional adds noted amid TA caution.
What is CrowdStrike's FY27 growth guidance?
FY27 guidance projects 20-25% growth, reflecting a slowdown from prior 35% rates. This contributed to post-earnings volatility.
Q4 FY26 Flex $1.69B +120%/$1B net new ARR +25%/FCF $376M but 7.5% post-earn slide ~$399/dip $398-417 bounce +5.88% Apr7 (CRWL ETF +5%)/TA bearish to $368/growth slowdown 35% to 22-23%/FY27 guide 20-25%; 8-K $500M buyback total $1.5B/CFO 'valuation disconnect'/Gartner MDR 98%/Cramer buy opp; YTD -12.1%/PT $400s-$520/$505 med 20% up/Zacks 105x. Minor insti adds/TA caution.